Lidocaine/tetracaine topical cream - Crescita Therapeutics

Drug Profile

Lidocaine/tetracaine topical cream - Crescita Therapeutics

Alternative Names: Flexicaine; Pliaglis; S-Caine™ Peel; Tetracaine/lidocaine topical cream - Crescita Therapeutics

Latest Information Update: 17 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ZARS
  • Developer Crescita Therapeutics; Galderma; Nuvo Research
  • Class Acetanilides; Aminobenzoic acids; Local anaesthetics; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Procedural pain
  • Phase II Unspecified
  • Discontinued Postherpetic neuralgia

Most Recent Events

  • 15 Aug 2017 Crescita Therapeutics has patent protection for Lidocaine/tetracaine topical cream in USA
  • 25 Apr 2017 Lidocaine/tetracaine topical cream licensed to Taro Pharmaceuticals Inc in USA
  • 09 Sep 2016 Lidocaine/tetracaine topical cream - Crescita Therapeutics is available for licensing in Mexico as of 09 Sep 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top